Live
When will the FDA approve Intellia Therapeutics' lonvo-z? — Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
Starts:Mar 24, 2026, 2:00 PMEnds:Jan 1, 2028, 4:59 AM
AZRGMIKSHLMTNVGPLYPMU
Total volume
$6.5K
Largest spread
—
Outcomes
3
Platforms
1
Markets
1
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Volume | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|---|
Before 2028 Favorite | 92.0%Kalshi | $611 | — | — | — | — | — | — | |
Before July 2027 | 91.0%Kalshi | $4.7K | — | — | — | — | — | — | |
Before October 2027 | 91.0%Kalshi | $1.1K | — | — | — | — | — | — |
Before 2028Favorite
92.0%Best · Kalshi$611
Before July 2027
91.0%Best · Kalshi$4.7K
Before October 2027
91.0%Best · Kalshi$1.1K
AI-generated summary, may be inaccurate.
A detailed summary of this event hasn't been generated yet. Once available, it will explain the context, key contenders, and what each outcome resolves to.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.